Boston Scientific is trading 8.3% up at $49.90 after reporting stronger-than-expected Q2 2026 results and updating investors on a major restructuring plan.
- Net sales grew 7.5% to $5.442 billion with adjusted EPS rising to $0.86, both topping analyst estimates.
- Management outlined margin-defense initiatives and updated guidance, while the stock also benefited from a broad healthcare sector rally following multiple Q2 earnings beats.